quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·1627d
PRRelease
Myovant Sciences Ltd. logo
Urovant Sciences Ltd. logo

Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients

MYOV· Myovant Sciences Ltd.UROV· Urovant Sciences Ltd.
Health Care
Original source

Companies

  • MYOV
    Myovant Sciences Ltd.
    Health Care
  • UROV
    Urovant Sciences Ltd.
    Health Care

Recent analyst ratings

  • Oct 26MYOVUpdateEvercore ISI-
  • Aug 9MYOVUpdateSVB Leerink$23.00
  • Feb 16MYOVUpdateSVB Leerink$19.00
  • Jan 5MYOVUpdateSVB Leerink$21.00
  • Oct 27MYOVUpdateSVB Leerink$23.00
  • Sep 9MYOVUpdateSVB Leerink$24.00

Related

  • SEC1130d
    SEC Form 15-12G filed by Myovant Sciences Ltd.
  • SEC1134d
    SEC Form EFFECT filed by Myovant Sciences Ltd.
  • SEC1134d
    SEC Form EFFECT filed by Myovant Sciences Ltd.
  • SEC1140d
    SEC Form 25-NSE filed by Myovant Sciences Ltd.
  • INSIDER1140d
    SEC Form 4: Valente Nancy returned 3,673 shares to the company, closing all direct ownership in the company (withholding obligation)
  • INSIDER1140d
    SEC Form 4: Potter Myrtle S returned 3,673 shares to the company, closing all direct ownership in the company to satisfy tax liability
  • INSIDER1140d
    SEC Form 4: Merendino Lauren returned 169,538 shares to the company, closing all direct ownership in the company to satisfy withholding tax
  • SEC1140d
    SEC Form S-8 POS filed by Myovant Sciences Ltd.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022